Cognition Therapeutics Inc (NASDAQ: CGTX) kicked off on Friday, down -4.10% from the previous trading day, before settling in for the closing price of $0.79. Over the past 52 weeks, CGTX has traded in a range of $0.34-$2.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 4.65%. With a float of $35.21 million, this company’s outstanding shares have now reached $40.81 million.
Let’s look at the performance matrix of the company that is accounted for 28 employees. In terms of profitability, gross margin is 48.66%, operating margin of -15707.53%, and the pretax margin is -9212.37%.
Cognition Therapeutics Inc (CGTX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cognition Therapeutics Inc is 15.24%, while institutional ownership is 10.44%. The most recent insider transaction that took place on Mar 14 ’24, was worth 9,975. In this transaction CEO & President of this company bought 5,700 shares at a rate of $1.75, taking the stock ownership to the 291,345 shares.
Cognition Therapeutics Inc (CGTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.81% during the next five years compared to -21.09% drop over the previous five years of trading.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Take a look at Cognition Therapeutics Inc’s (CGTX) current performance indicators. Last quarter, stock had a quick ratio of 2.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.53 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Cognition Therapeutics Inc (NASDAQ: CGTX) saw its 5-day average volume 0.75 million, a negative change from its year-to-date volume of 1.39 million. As of the previous 9 days, the stock’s Stochastic %D was 71.70%. Additionally, its Average True Range was 0.08.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 43.57%, which indicates a significant increase from 39.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.42% in the past 14 days, which was lower than the 106.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5826, while its 200-day Moving Average is $1.1139. Nevertheless, the first resistance level for the watch stands at $0.7850 in the near term. At $0.8162, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8335. If the price goes on to break the first support level at $0.7365, it is likely to go to the next support level at $0.7192. Assuming the price breaks the second support level, the third support level stands at $0.6880.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
The company with the Market Capitalisation of 31.32 million has total of 41,548K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -25,790 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -9,940 K.
